• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
×

Target

Host

Species Reactivity

Species Reactivity

Conjugate

Conjugate

  • Featured Product
  • KD/KO Validated

TMEM106B Monoclonal antibody, PBS Only

TMEM106B Monoclonal Antibody for WB, IP, Indirect ELISA

Host / Isotype

Mouse / IgG1

Reactivity

human

Applications

WB, IP, Indirect ELISA

Conjugate

Unconjugated

CloneNo.

5D1F8

Cat no : 60333-1-PBS

Synonyms

TMEM106B, transmembrane protein 106B

Validation Data Gallery

Filter:
  • Western Blot (WB) analysis of various lysates using TMEM106B Monoclonal antibody (60333-1-Ig)

    WB analysis using 60333-1-Ig (same clone as 60333-1-PBS)

    Various lysates were subjected to SDS PAGE followed by western blot with 60333-1-Ig (TMEM106B antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 60333-1-PBS in a different storage buffer formulation.

  • Western Blot (WB) analysis of HeLa cells using TMEM106B Monoclonal antibody (60333-1-Ig)

    WB analysis of HeLa using 60333-1-Ig (same clone as 60333-1-PBS)

    WB result of TMEM106B antibody (60333-1-Ig; 1:2000; room temperature for 1.5 hours) with wild-type and TMEM106B knockout HeLa cells. This data was developed using the same antibody clone with 60333-1-PBS in a different storage buffer formulation.

  • Western Blot (WB) analysis of HeLa cells using TMEM106B Monoclonal antibody (60333-1-Ig)

    WB analysis of HeLa using 60333-1-Ig (same clone as 60333-1-PBS)

    HeLa cells were subjected to SDS PAGE followed by western blot with 60333-1-Ig (TMEM106B antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 60333-1-PBS in a different storage buffer formulation.

  • Western Blot (WB) analysis of various lysates using TMEM106B Monoclonal antibody (60333-1-Ig)

    WB analysis using 60333-1-Ig (same clone as 60333-1-PBS)

    Various lysates were subjected to SDS PAGE followed by western blot with 60333-1-Ig (TMEM106B antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 60333-1-PBS in a different storage buffer formulation.

  • Immunoprecipitation (IP) experiment of HeLa cells using TMEM106B Monoclonal antibody (60333-1-Ig)

    IP experiment of HeLa using 60333-1-Ig (same clone as 60333-1-PBS)

    IP result of anti-TMEM106B (IP:60333-1-Ig, 5ug; Detection:60333-1-Ig 1:500) with HeLa cells lysate 1720 ug. This data was developed using the same antibody clone with 60333-1-PBS in a different storage buffer formulation.

Tested Applications

Recommended dilution

ApplicationDilution
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Product Information

60333-1-PBS targets TMEM106B in WB, IP, Indirect ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Immunogen TMEM106B fusion protein Ag21448 相同性解析による交差性が予測される生物種
Full Name transmembrane protein 106B
Calculated molecular weight 31 kDa
Observed molecular weight ~40 kDa
GenBank accession numberBC033901
Gene symbol TMEM106B
Gene ID (NCBI) 54664
Conjugate Unconjugated
Form Liquid
Purification MethodProtein G purification
Storage Buffer PBS Only
Storage ConditionsStore at -80°C.

Background Information

TMEM106B is a genetic risk factor for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). Amyotrophic lateral sclerosis (ALS), like FTLD-TDP, is characterized by pathological TDP-43 inclusions. TMEM106B expression in the brain may be linked to mechanisms of disease in FTLD-TDP and risk alleles confer genetic susceptibility by increasing gene expression.